On August 6, 2026, the U.S. FDA released a revised edition of the Dietary Supplement Ingredient Import Compliance Alert, clearly stating that, effective October 1, 2026, when dietary supplement ingredients are declared in the form of amino acid chelates, importers must simultaneously submit, through the FDA Prior Notice system, a GMP compliance certificate issued by an organization accredited under ISO/IEC 17065 when the ingredients enter the U.S. market. For Chinese amino acid manufacturers, U.S. importers, and parties involved in customs declaration and supply chain services, this change deserves attention because it directly concerns the completeness of declaration documents for amino acid exports to the United States, the market-entry coordination process, and customs clearance timeliness.

What declaration requirements have been clarified in this revision?

According to the information disclosed, the U.S. FDA updated the Dietary Supplement Ingredient Import Compliance Alert on August 6, 2026. The revision states that, effective October 1, 2026, all dietary supplement ingredients declared in the form of amino acid chelates must be accompanied by a third-party GMP compliance certificate submitted by the importer through the FDA Prior Notice system.

The certificate must be issued by an organization accredited under ISO/IEC 17065. Examples of amino acid chelates listed in the summary include iron glycinate and zinc lysinate. The confirmed information also indicates that this requirement will directly affect the market-entry process and customs clearance timeliness for Chinese amino acid manufacturers exporting to the United States.

The initial impact will be on the coordination of declaration, procurement, and delivery

For ingredient companies directly involved in exports to the United States

Based on the analysis, the parties most directly affected are manufacturers and trading companies supplying amino acid chelate ingredients to the U.S. market. This is because the new requirement does not remain at the product-description level; instead, it directly enters the chain of import declaration documents. For these companies, the impact will mainly be reflected in customer market-entry communications, the pace of document preparation, and compliance coordination before shipment. At present, greater attention should be paid to whether orders already in transit, orders in production scheduling, and batches about to enter the declaration window can be matched with the certificate submission requirement in a timely manner.

For U.S. importers and ingredient purchasers

From a business-role perspective, importers are directly responsible for submitting information through the Prior Notice system, so their focus will be on the completeness of supporting documents and control of the declaration timing. Purchasers will need to further confirm whether the ingredients being purchased fall within the scope of ingredients declared in the form of amino acid chelates, as well as whether the relevant suppliers can provide a compliant third-party GMP certificate on time. This indicates that procurement decisions will no longer focus solely on price, delivery time, and specifications, but will also place greater emphasis on whether compliance documents can be provided at the same time.

For customs declaration, logistics, and supply chain service providers

For supply chain service companies, the potential impact of this revision will focus on customs clearance document review, declaration coordination, and time-efficiency management. Since the new requirement is directly related to submission through the Prior Notice system, service providers will need to become involved earlier to verify the documents. If the preparation, transmission, or matching of certificates contains discrepancies, the pressure will often first be reflected in the customs declaration schedule and overall delivery timeline. Accordingly, process coordination will become a practical priority in this round of changes.

What practical issues should companies focus on now?

First confirm whether the products fall within the declaration scope

For companies already conducting business with the United States, the first step is to verify which products in their export portfolio are declared in the form of amino acid chelates. The key issue is not limited to the product name; it also includes the actual declaration approach and the classification method used by the customer. If there are discrepancies among the company's internal product definitions, sales descriptions, and declaration documents, communication deviations may easily arise during subsequent implementation.

Move certificate preparation forward to the pre-shipment process

From a practical perspective, the certificate requirement is now linked to the import declaration process, so document preparation cannot be postponed until the customs clearance stage is approaching. Relevant companies need to focus on obtaining and transmitting the third-party GMP compliance certificate and ensuring its correspondence with the relevant order batches. For companies with relatively decentralized supplier management, this step requires particularly early planning.

Review the coordination mechanism with customers and importers at the same time

The submission takes place through the importer's operation of the Prior Notice system. Therefore, even if an export company is not the party making the direct submission, it cannot leave all compliance responsibilities to the customer. More practically, the focus should be on whether both parties have clearly defined the document provision milestones, file formats, division of responsibilities, and remedial arrangements in the event of an exception. These coordination details will directly affect execution efficiency.

Continue monitoring subsequent wording and implementation practices

What is currently known is that the revised guidance has clarified the certificate submission requirement and its effective date. However, companies still need to continue monitoring whether subsequent official statements provide further details. In particular, any supplementary explanation concerning the specific scope of application, implementation practices, and coordination with actual declarations will affect companies' internal process design and customer communication methods.

This is more like a signal that the compliance threshold is moving forward

This information should not be understood merely as a new document requirement. It is more appropriately viewed as a signal that the United States is moving the review of import documentation for certain dietary supplement ingredients further forward. It does not directly rewrite all business conditions, but it has already shifted compliance certification from an internal quality management issue to the level of external verification in import declarations.

From an industry perspective, this change currently has both a clearly specified effective date and room for continued observation at the implementation level. What is clear is that the import declaration requirements for amino acid chelate-related ingredients have been incorporated into the revised guidance. What remains to be observed is how different market participants will absorb this requirement and what kind of linkage will develop between document preparation and actual customs clearance efficiency.

In the short term, this is an operational change; in the long term, it is still a competition in compliance capabilities

Overall, the immediate impact of this information will be changes to declaration documents and delivery processes. Companies need to promptly incorporate product-scope confirmation, certificate preparation, and customer coordination into their existing export operations. In the longer term, the signal it sends is that, for dietary supplement ingredients entering the U.S. market, merely meeting supply conditions is no longer sufficient. The ability to synchronize verifiable compliance documents with trade processes is becoming increasingly important.

Accordingly, this update is currently better understood as a compliance requirement that has been clearly implemented, as well as an industry development whose implementation details still require continuous monitoring. For relevant companies, the priority is not to make an emotional judgment about the size of the impact, but to promptly identify the affected product categories and business stages and reduce the risk of being placed in a passive position in market entry and customs clearance after the effective date.

Basis of this article and directions for further verification

This article was generated based on the information title, event date, and event summary provided by the user. The core information includes: the U.S. FDA's update of its import compliance guidance for dietary supplement ingredients; the relevant requirements taking effect on October 1, 2026; and the requirement that amino acid chelate ingredients be accompanied in the Prior Notice system by a GMP compliance certificate issued by an organization accredited under ISO/IEC 17065.

Generally speaking, this type of information can subsequently be verified on an ongoing basis by consulting official announcements, corporate announcements, industry association information, authoritative media reports, and documents issued by standards organizations. It should be noted that the input information does not provide a specific official source link. Therefore, the original relevant documents, supplementary explanations, and subsequent implementation practices still require further verification. Key areas to monitor include whether the authorities issue further explanations, whether more detailed applicability guidance emerges during the actual declaration process, and how market participants adjust delivery cycles and customs clearance arrangements.